Insilico Medicine has nominated its second preclinical drug candidate from its Abu Dhabi R&D facility — a painkiller with the potential to offer a non-addictive alternative to opioids. The Boston-based biotech used AI to discover the drug in one year, compared to an industry average of 4.5 years. The pharmaceutical candidate is on track to begin human trials in 2027.

This is Insilico's second preclinical candidate from the UAE. The first, nominated earlier this year, targeted glioblastoma, an aggressive form of brain cancer....

More https://bit.ly/3RDvujz

Via uaepreferred.com/